Clinical course and prognosis in patients with hypertrophic cardiomyopathy are characterised by life threatening arrhythmias and sudden cardiac death. The prognostic significance of these factors' has been well recognised but other factors-such as the evolution of "typical" hypertrophic cardiomyopathy into a dilated form with systolic dysfunction-have been studied only rarely, and the impact of this particular subgroup on cardiac morbidity and mortality is not precisely known (for references see table  1 ). This is due in part to the fact that the frequency with which left ventricular dilatation 
Abstract Background-To determine the incidence and prognosis of left ventricular dilatation and systolic dysfunction in 139 patients with hypertrophic cardiomyopathy during long term follow up. Methods-Left ventricular chamber dilatation and systolic dysfunction (both together referred to as left ventricular chamber dilatation) were determined echocardiographicaily. Chamber dilatation was defined as an increase in the left ventricular end diastolic diameter of >2% per year combined with a decrease in midventricular systolic fractional shortening of >2% per year of follow up [10.3 (SD 6) years]. The predictive value for left ventricular chamber dilatation of clinical, invasive, and echocardiographic variables and its prognosis were assessed.
Results-In 119 of 139 individuals (86%), left ventricular chamber size and systolic function remained stable (group 1), and in 20/139 patients (14%) left ventricular chamber dilatation occurred during follow up (group 2). At baseline examination, symptoms such as dyspnoea and syncope occurred less often in group 1 than in group 2; New York Heart Association classification was lower in group 1 than in group 2 (P = 0.001). Left ventricular mass index relative to sex specific normal values was increased by 18% in group 1 and by 41% in group 2 (P = 0.04). Cumulative survival rates were slightly although not significantly higher in group 1 than in group 2. Event-free survival was significantly higher in group 1 than in group 2 (P < 005). Clinical course and prognosis in patients with hypertrophic cardiomyopathy are characterised by life threatening arrhythmias and sudden cardiac death. The prognostic significance of these factors' has been well recognised but other factors-such as the evolution of "typical" hypertrophic cardiomyopathy into a dilated form with systolic dysfunction-have been studied only rarely, and the impact of this particular subgroup on cardiac morbidity and mortality is not precisely known (for references see table  1 ). This is due in part to the fact that the frequency with which left ventricular dilatation and systolic dysfunction occurs in hypertrophic cardiomyopathy is uncertain. 1"12 There are only a few studies'F"2 which have provided some insight into the pathophysiological mechanisms involved in this subgroup of patients with hypertrophic cardiomyopathy. The development of progressive systolic dysfunction has been reported to occur more often in surgically treated patients than in medically treated patients. '6 The purpose of the present retrospective study was therefore (1) (fig 2A) and the relative increase in left ventricular fractional shortening (fig 2B) , respectively during follow up.
Comparison between medical and surgical therapy Left ventricular chamber dilatation and systolic dysfunction (group 2) occurred in 8% 
Clinical data
The following clinical variables remained unchanged during follow up in either group: body surface area, body mass index, heart rate, blood pressure, frequency of angina pectoris, premature ventricular beats, atrial fibrillation, physical working capacity, and Sokolow-Lyon index.
The occurrence of dyspnoea remained conEnd diastolic diameter v relative muscle mass index stant during follow up in group 1 (from 43/119 = 36% to 45/119 = 38%), but decreased significantly in group 2, from 20/20 = 100% to 10/20 = 50% (P = 0-03), which may be related to the fact that 15 of the 20 patients in this group had successful surgical treatment. In groups 1 and 2, the frequency of syncope decreased from 13/119 = 11% to 1/119 = 1% (NS), and from 8/20 = 40% to 3/20 = 17% (P = 0-05), respectively, during follow up. Palpitations were reported to a similar degree in group 1 (approximately 30%) and group 2 (50% at baseline and 33% at follow up examination, NS). NYHA classification did not change in group 1, but decreased during follow up from 2-5 (0 6) to 1-5 (0 5) in group 2 (P = 0-004).
Echocardiographic data Posterior wall thickness did not change during follow up in either one of the two groups.
End diastolic diameter remained constant in relative (-0-3%/year of follow up) and absolute terms in group 1 and increased significantly in group 2 ( fig 3A; relative increase Follow up (years) 20 25 group The findings of our study suggest that nontransmural myocardial infarction(s) most probably occur, which are caused by a mismatch of oxygen supply and demand due to severe myocardial hypertrophy.25 Several investigations have reported a reduction in myocardial perfusion in patients with hypertrophic cardiomyopathy supposedly leading to myocardial scarring. 26 27 Severe left ventricular hypertrophy as a cause for enhanced interstitial fibrosis has been reported in patients with severe valvular disease and heart failure. The exact process which is responsible for this scarring is not yet known but is thought to be the result of the stimulation of the renin-angiotensin system or of aldosterone production in patients with congestive heart failure. Other mechanisms might be involved as well, such as immunological or inflammatory processes. It has been reported that small intramural coronary arteries are abnormal in about 80% of patients with hypertrophic cardiomyopathy and that abnormal small arteries are observed more often within areas of fibrosis. 27 28 Another mechanism for left ventricular dilatation is a disruption of left ventricular geometry after septal myectomy.'6 This mechanism is supported by the fact that patients undergoing septal myectomy less often developed left bundle branch block in group 1 (from 37% preoperatively to 72% postoperatively) than those in group 2 (from 0% to 63%). Septal thinning after myectomy has been described previously'6 and has been attributed to the disruption of left ventricular geometry.
PROGNOSIS
The one year mortality in patients with hypertrophic cardiomyopathy has been reported to range between 3% and 8%,' 17 29 and the five year cumulative survival rate between 55% and 75%.1729 The annual as well as the five and 10 year survival rates found in this study were better than those previously reported. It has been shown'7 that the relatively low mortality in our study is mainly the result of the low mortality in surgically treated patients. The apparent inconsistency that the annual mortality rate in the group with ventricular dilatation is low and even lower than that in the control group is probably related to the small number of patients and consequently to the small number of deaths in group 2. Assuming an incidence of ventricular dilatation of approximately 15% during an average follow up of 10 years, the patient population would need 1200 individuals for differences in cumulative survival between patients with and without ventricular dilatation to be detected with a statistical significance of P < 0 05 at five, 10, and 20 years. Such a sample size would exceed the highest study populations presently reported (n = 600)30 by 100%.
Despite the fact that signs and symptoms typical of hypertrophic cardiomyopathy improved more in the group with than in the group without ventricular dilatation (table 5) , the event-free survival was significantly better in the patients who did not develop ventricular dilatation than that in those who did (fig 4) . This is consistent with the notion that prognosis for quality of life is worse in patients with than in those without ventricular dilatation, because patients in group 2 were significantly more symptomatic at baseline examination than those in group 1.
STUDY LIMITATIONS
One major limitation of the present study is that this was a retrospective analysis. Due to patient selection, the systolic pressure gradient across the left ventricular outflow tract was significantly different between medically and surgically treated patients. Because of the long observation period of up to 32 years and the relatively low incidence of the disease, and because for ethical reasons randomisation could not be performed, this, like all previously reported follow up studies in patients with hypertrophic cardiomyopathy, was based on retrospective data.
In 26 patients (22 in group 1 and four in group 2), entry into the study (time of diagnosis) did not coincide with the baseline echocardiographic evaluation because echocardiography was not available at that time. Analysing our data under the assumption that study entry in these 26 patients occurred at the time of their first echocardiogram did not change the findings of the present study but reduced the time of follow up for the entire study group from 10-3 to 8&8 years.
The formula for calculation of left ventricular mass22 used in this study might cause somewhat inaccurate results because of changes in left ventricular geometry in patients with hypertrophic cardiomyopathy. The left ventricular cavity does not really resemble an ellipsoid, the shape of which is the basis for the calculation of left ventricular mass by echocardiography. Unfortunately, no alternative way of calculating left ventricular mass by echocardiography is available. The ratio of patients with or without obstruction was similar in both study groups. Therefore the error of using the formula of Troy and Devereux22 was equally distributed among the study patients.
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